Readily3D
Readily3D SA is a Lausanne-based Swiss spin-out of EPFL that develops and sells the Tomolite, a tomographic volumetric 3D bioprinter that solidifies cell-laden inks with shaped light from multiple angles to build centimeter-scale living tissue constructs in seconds for life-science research, pharmaceutical and academic medical-center customers.
- Company typePrivate
- Founded2020
- HeadquartersLausanne, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Readily3D does
Readily3D SA is a privately held Swiss developer of volumetric 3D bioprinters headquartered at the EPFL Innovation Park in Lausanne. The company commercializes a tomographic volumetric bioprinting technology originally invented by co-founders Paul Delrot and Prof. Christophe Moser during research at EPFL; in this approach, shaped light beams from multiple angles simultaneously solidify photosensitive, cell-laden inks throughout a build volume, producing centimeter-scale biological constructs (including organoids and vascular-network-bearing tissues) in seconds rather than the minutes-to-hours of conventional layer-by-layer extrusion bioprinters. Readily3D's technology is contactless and reportedly preserves high cell viability (>95% at 10 days for human hepatic organoids, >90% at 7 days for C2C12 myoblasts and normal human dermal fibroblasts) at optical resolution below 100 µm with low photoinitiator content (1 mg/mL LAP) and light dose (<600 mJ/cm²).
The commercial product line consists of the Tomolite v2.0 modular volumetric bioprinter (offered in Standard, E, Performance and Polychromatic configurations), the Apparite software platform (STL import, light-dose computation, object registration, live monitoring, cloud-accelerated beam computation in roughly 30-90 seconds), and a Multi-wavelength Add-on supporting up to four laser lines from 400 nm to 750 nm developed under the EU Horizon 2020 ENLIGHT project. The company is monetized through direct, quote-based hardware sales (Tomolite systems and add-on modules) supported by Apparite software and technical support services, with no disclosed resale or distribution channel. Go-to-market relies on direct enterprise sales, the appointment of Randy Heyler as North America business developer, scientific-conference presence (European Organ-on-chip Society, European Society for Biomaterials, Summer School on Light-Based 3D Printing) and a publication-driven credibility strategy anchored by more than 50 peer-reviewed papers.
The core customer segments are life-science researchers in academia, pharmaceutical and biotech companies, and academic medical centers such as Utrecht University and University Medical Center Utrecht, where the platform is used for biofabrication, organoid biology, disease modeling, tissue regeneration and drug discovery. The company is funded primarily through non-dilutive sources — a Venture Kick award, MassChallenge participation and two ongoing Eurostars/Eureka grants (VOLTA-E, December 2023 - September 2026; PREPPER-E, December 2024 - December 2026) — with no disclosed equity financing. Intellectual property is anchored by 16 granted patents spanning the US, Europe, Japan, China, Korea, Singapore and Australia.
Readily3D firmographics
Firmographics- Name
- Readily3D
- Legal name
- Readily3D SA
- Website
- https://readily3d.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Readily3D SA is a Lausanne-based Swiss spin-out of EPFL that develops and sells the Tomolite, a tomographic volumetric 3D bioprinter that solidifies cell-laden inks with shaped light from multiple angles to build centimeter-scale living tissue constructs in seconds for life-science research, pharmaceutical and academic medical-center customers.
- Ownership category
- akta.pro rank
Readily3D industry classification
Industry- Product category
- 3D Bioprinters
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)
- akta.pro secondary industries
- 3D Printers (Additive Manufacturing) (HDACAEAH), Medical & Dental Prototyping (Models, Guides, Pre-Op Planning) (IMAAAFAI), 3D Printer Automation & Peripheral Hardware (Material Handling, Depowdering, Build Units) (IMAAAAAL)
Keywords
Where Readily3D is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Readily3D business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Tomolite Bioprinter Sales: Sale of Tomolite v2.0 modular tomographic volumetric bioprinter with different versions (Standard, E, Performance, Polychromatic). One-time hardware purchase with potential add-on modules.
- Apparite Software License: Software platform for bioprinter operation. Supported on Windows 7 and 10. Likely sold as license with potential for updates and support contracts.
- Multi-wavelength Add-on Module: Modular add-on for Tomolite v2 enabling multi-wavelength printing. Can be purchased as upgrade to existing systems or bundled with new purchases.
- Technical Support and Services: Technical support services including online appointments for technical inquiries. Professional services for setup and training likely available.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Custom quotation-based pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Readily3D product offering
Product offeringCore offering
Readily3D manufactures and sells the Tomolite, a tomographic volumetric 3D bioprinter that fabricates centimeter-scale living tissue and organoid constructs in a single light-projection step (typically 10–30 seconds). The hardware is operated through its companion Apparite software and can be extended with a multi-wavelength add-on for multi-material and multi-cell printing.
Product overview
Readily3D offers a modular volumetric 3D bioprinting system consisting of the Tomolite bioprinter as the core hardware platform, supported by the Apparite software for workflow control. The Tomolite v2.0 supports modular upgrades including the Multi-wavelength Add-on for polychromatic printing applications. The company also develops add-on modules and software enhancements to extend the platform's capabilities for life science research.
Differentiator
Problem solved
Functional benefit
Brands
- Tomolite: Volumetric bioprinter product line including Tomolite v2.0 with versions: Standard, E, Performance and Polychromatic.
- Apparite
- Tomolite Add-on
Products and services
- Tomolite v2.0 Bioprinter
- Apparite Software
- Multi-wavelength Add-on
Quantifiable outcome
- Human hepatic organoids: >95% viability after 10 days, printed in 15.5 seconds
- +5 more outcomes
Companies that use Readily3D
Customer profileSegments3 records
Ideal customer profiles3 records
Readily3D technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Readily3D partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Eurostars (Eureka Network)coreOngoing Eurostars VOLTA-E!3908 project (December 2023 - September 2026) and Eurostars PREPPER-E!6780 (December 2024 - December 2026) supported by Eureka Network. These R&D projects advance volumetric bioprinting applications and technology development.
- EPFL (École Polytechnique Fédérale de Lausanne)coreCore technology originated from EPFL research. Prof. Christophe Moser, full professor at EPFL, is co-founder and board member. Company is based at EPFL Innovation Park. Ongoing technology transfer and research collaboration.
- Utrecht University / University Medical Center UtrechtminorProf. Riccardo Levato, associate professor at Utrecht University and UMC Utrecht, serves as scientific advisor. He pioneered volumetric bioprinting for tissue printing and contributes expertise in bioprinting applications.
- European Union Horizon 2020 (ENLIGHT Project)coreMulti-wavelength add-on developed as outcome of ENLIGHT project, funded by European Union's Horizon 2020 research and innovation program under grant agreement No. 964497.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Readily3D competitors and assessment
Company assessmentDirect peers
- Poietis: French bioprinting company using laser-assisted bioprinting for tissue engineering and pharmaceutical applications. Comparable as a European bioprinting technology company targeting pharma R&D and regenerative medicine use cases.
- RegenHU: Swiss bioprinter manufacturer offering modular multi-head bioprinters for tissue engineering and regenerative medicine research. Comparable as a Europe-based bioprinting hardware vendor with modular product design serving academic and pharma research.
- Aspect Biosystems: Developer of microfluidic 3D bioprinting technology for tissue therapeutics and preclinical drug testing. Comparable as a bioprinting platform targeting pharma/biotech partnerships in tissue engineering and drug discovery.
- Organovo: Pioneer in 3D bioprinted human tissue for drug discovery and disease modeling. Comparable as a bioprinting-focused life science tools company pursuing pharma and academic customers with tissue construct outputs.
- GeSiM: German manufacturer of specialized 3D bioprinters and bio-printing platforms for research applications. Comparable as a small European bioprinter vendor serving academic tissue engineering and regenerative medicine labs.
- BICO (formerly CELLINK): Largest dedicated bioprinting company globally, offering extrusion-based BIO X and other 3D bioprinters, bioinks, and lab automation. Directly comparable as a bioprinter vendor serving tissue engineering and pharma research customers, though operating at vastly larger scale with a broader bioink/consumables revenue model.
- Allevi (a 3D Systems company): Bioprinter and bioink vendor acquired by 3D Systems, offering extrusion-based 3D bioprinters for life science research. Comparable as a bioprinting platform targeting academic tissue engineering and drug discovery labs.
Broad incumbents
- 3D Systems: Large incumbent in 3D printing with extensive medical/life science offerings including the Allevi bioprinting line and regenerative medicine programs. Comparable as a broad medical 3D printing player, though bioprinting is a small part of its portfolio.
- Stratasys: Major 3D printing incumbent with PolyJet and FDM technologies serving healthcare and life sciences. Comparable as a broader 3D printing hardware company with medical/healthcare adjacencies, though not a bioprinting specialist.
Emerging players
- Brinter: Finnish modular 3D bioprinter company targeting tissue engineering and pharma research with multi-material printing capabilities. Comparable as an emerging European modular bioprinter vendor focused on academic and translational research customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Readily3D social profiles
Digital presenceReadily3D financial estimates
Financial estimateRevenue estimate
Valuation estimate
Readily3D leadership team
Management profileNumber of profiles
Profiles5 records
Readily3D funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Readily3D M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Readily3D
What does Readily3D do?
Readily3D manufactures and sells the Tomolite, a tomographic volumetric 3D bioprinter that fabricates centimeter-scale living tissue and organoid constructs in a single light-projection step (typically 10–30 seconds). The hardware is operated through its companion Apparite software and can be extended with a multi-wavelength add-on for multi-material and multi-cell printing.
Is Readily3D a public or private company?
Readily3D is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Readily3D founded?
Readily3D was founded in 2020. It employs 1 to 10 people.
Where is Readily3D based?
Readily3D is headquartered in Lausanne, Switzerland, in the Europe region.
How does Readily3D make money?
Four revenue lines are on record. Tomolite Bioprinter Sales are the primary driver. The others are apparite Software License, multi-wavelength Add-on Module and technical Support and Services.
Who are Readily3D's main competitors?
Direct peers on record are Poietis, RegenHU, Aspect Biosystems, Organovo, GeSiM, BICO (formerly CELLINK) and Allevi (a 3D Systems company). Broad incumbents are 3D Systems and Stratasys. Brinter is listed as an emerging player.
Does Readily3D have an API?
No public API is recorded for Readily3D.
What industry is Readily3D in?
Readily3D's product category is 3D Bioprinters. Its primary akta.pro industry code is IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware), with a secondary code of HDACAEAH, 3D Printers (Additive Manufacturing). Its NAICS code is 3391 and its SIC code is 3841.